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ABSTRACT 
Momordica charantia (bitter gourd) is not only a nutritious vegetable but it is also used in 
traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with 
animals and humans suggested that the vegetable has a possible role in glycaemic control. To 
assess the effects of mormodica charantia for type 2 diabetes mellitus. Several electronic 
databases were searched, among these were The Cochrane Library (Issue 1, 2012), 
MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined 
with handsearches. No language restriction was used. We included randomised controlled 
trials (RCTs) that compared momordica charantia with placebo or a control intervention, with 
or without pharmacological or non-pharmacological interventions. Two authors 
independently extracted data. Risk of bias of the trials was evaluated using the parameters of 
randomisation, allocation concealment, blinding, completeness of outcome data, selective 
reporting and other potential sources of bias. A meta-analysis was not performed given the 
quality of data and the variability of preparations of momordica charantia used in the 
interventions (no similar preparation was tested twice). Four randomised controlled trials 
with up to three months duration and investigating 479 participants met the inclusion criteria. 
Risk of bias of these trials (only two studies were published as a full peer-reviewed 
publication) was generally high. Two RCTs compared the effects of preparations from 
different parts of the momordica charantia plant with placebo on glycaemic control in type 2 
diabetes mellitus. There was no statistically significant difference in the glycaemic control 
with momordica charantia preparations compared to placebo. When momordica charantia 
was compared to metformin or glibenclamide, there was also no significant change in reliable 
parameters of glycaemic control. No serious adverse effects were reported in any trial. No 
trial investigated death from any cause, morbidity, health-related quality of life or costs. 
There is insufficient evidence on the effects of momordica charantia for type 2 diabetes 
mellitus. Further studies are therefore required to address the issues of standardization and the 
quality control of preparations. For medical nutritional therapy, further observational trials 
evaluating the effects of momordica charantia are needed before RCTs are established to 
guide any recommendations in clinical practice. 
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